Cannabinoid product developer GW Pharmaceuticals PLC (Nasdaq:GWPH) has revealed more good phase III data for its Epidiolex drug for epilepsy sufferers.
In two types of epilepsy, Dravet Syndrome and Lennox-Gastaut Syndrome, Epidiolex reduced the number of seizures compared to the placebo during both the 14 week treatment period and 12 week maintenance period.
“We are pleased to present key findings from two pivotal Phase 3 studies of Epidiolex and believe these additional positive data reinforce the robust nature of the results achieved in two of the most difficult-to-treat epilepsy patient populations,” said Justin Gover, GW’s chief executive.
He added it was making good progress both towards a new drug admission for Epidiolex in the US and a commercial launch.
Orrin Devinsky, principal investigator of the Dravet syndrome trial, said he and his colleagues were excited by the prospect of prescribing an appropriately standardized and tested pharmaceutical formulation of cannabidiol.”
“Dravet syndrome and Lennox-Gastaut syndrome are diagnosed in early childhood and represent some of the most difficult types of epilepsy to treat.
“Nearly all patients continue to have uncontrolled seizures and other medical needs throughout their lifetime,” he said.
Shares rose 5% to US$117.6.